Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866
about
Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzymeThe evolutionary portrait of metazoan NAD salvageA phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPTStructure and reaction mechanism of human nicotinamide phosphoribosyltransferaseStructural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferasePhosphoribosyl Diphosphate (PRPP): Biosynthesis, Enzymology, Utilization, and Metabolic Significance.Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD"Clocks" in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and agingNicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery.Benefits of healthy adipose tissue in the treatment of diabetes.Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.The NAD World: a new systemic regulatory network for metabolism and aging--Sirt1, systemic NAD biosynthesis, and their importanceIs PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome?Dissecting systemic control of metabolism and aging in the NAD World: the importance of SIRT1 and NAMPT-mediated NAD biosynthesis.Nicotinamide Phosphoribosyltransferase in Human Diseases.Unique Toll-Like Receptor 4 Activation by NAMPT/PBEF Induces NFκB Signaling and Inflammatory Lung InjuryPre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions.Nicotinamide phosphoribosyltransferase (Nampt): a link between NAD biology, metabolism, and diseases.Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes.Nampt: linking NAD biology, metabolism and cancer.From heterochromatin islands to the NAD World: a hierarchical view of aging through the functions of mammalian Sirt1 and systemic NAD biosynthesis.The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumors.Visfatin: a potential therapeutic target for rheumatoid arthritis.PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?Adipose tissue, hormones, and treatment of type 1 diabetes.The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia.Physiological and pathophysiological roles of NAMPT and NAD metabolism.Analysis of the nicotinamide phosphoribosyltransferase family provides insight into vertebrate adaptation to different oxygen levels during the water-to-land transition.Crystallization of human nicotinamide phosphoribosyltransferaseProinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity.Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase.Plasma visfatin levels in pregnant women with normal glucose tolerance, gestational diabetes and pre-gestational diabetes mellitus.NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR.Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA.Chicken Is a Useful Model to Investigate the Role of Adipokines in Metabolic and Reproductive Diseases.
P2860
Q24299618-0F9C0FB3-3138-43BF-9A37-C00E62FB223DQ27318392-EBFF17C4-8E8C-481E-B9A7-0E8FF3D6CB93Q27656939-1A5FB6D2-530A-4380-8E72-1FDE7281F3DEQ27657748-C5AD377C-4FCC-447D-9728-65149CA5DB77Q27690154-B6B0E521-B32E-4D97-9C31-066837214DDFQ30396867-3BF4C955-881B-4184-8823-0CB16282692FQ33336612-701C4E54-99FA-49A7-BA27-DA1D60992089Q33915457-C1B21432-BE66-403A-95C2-0B03B11074F8Q34003813-93181146-A082-4074-8D56-9A0DD7D2CB40Q34023537-D6387135-53E0-41BB-83B3-B601F2608342Q34482044-F6E82031-AD50-494E-9A65-2D76F90DBCEEQ34917651-463EC96F-0EFA-4777-A5CA-E5B303804574Q34993305-D2790CA3-63D6-4E27-BF96-41B16F06AA8FQ35013606-6BF219A5-BFE3-4CB0-A476-0583976AF94DQ35581515-29D039F8-5E04-4AB9-81AB-0FA862F36E4CQ35953849-D3B0AB09-DC3E-43F4-A63F-04158A458DDEQ37216851-E853C917-C458-4B04-B4D6-1E67526917C4Q37324960-300B0BF1-C74D-4FF8-982C-AAB40BB944C1Q37324972-420B2781-D584-49F7-92D7-BA367EE89E8FQ37334248-EE4C702E-D67E-40C2-A532-62E3021D585DQ37346388-887A0FE2-A83D-448D-A7D1-FFFCCAD5C50EQ37410764-3E162746-EEA9-4766-A899-338809886E8CQ37690440-FE4C8793-5AB0-4886-AD34-C1ADEAC21555Q38005192-A054C8D2-1B5C-45DF-AAAA-AD6BD4EEBD4FQ38027744-4E98D8CE-4B44-49C8-9A31-976A13B42B37Q38522653-3A5B5B07-B610-47B5-B257-2FFFCAC20789Q38555243-CBEB18D4-4A52-4B4D-A2DA-A6946E0A3278Q40900460-9F940248-4747-442C-9D05-410E64D79AC0Q42001382-E99D94B2-ABCB-49D2-985E-14695EA21B50Q42119017-69DEEA1C-207B-4F27-BED3-FDC37125D4A6Q43160144-36C74485-1FE2-4D1B-8B18-4827A4F8401CQ43199251-57E8E3E0-C627-46D5-9F1D-3ED60ED02984Q49712935-A1B09E4D-56C8-462F-A298-0BE4EFD98594Q52316501-3AC65C88-0400-40BE-8E57-FF1328ABD750Q55690183-55AFE745-FC0D-4291-9E5B-ED3FCB38230F
P2860
Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866
description
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2006
@ast
im September 2006 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 2006/09/08)
@sk
vědecký článek publikovaný v roce 2006
@cs
wetenschappelijk artikel (gepubliceerd op 2006/09/08)
@nl
наукова стаття, опублікована у вересні 2006
@uk
مقالة علمية (نشرت في 8-9-2006)
@ar
name
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@ast
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@en
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@nl
type
label
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@ast
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@en
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@nl
prefLabel
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@ast
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@en
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@nl
P2093
P1476
Crystal structure of visfatin/ ...... h the anti-cancer agent FK-866
@en
P2093
Gil Bu Kang
Jae Bum Kim
Jun Hyuck Lee
Kyeong Kyu Kim
Mun-Kyoung Kim
Se Won Suh
Soo Hyun Eom
Soo Jeong Park
Sung Hyun Kim
P356
10.1016/J.JMB.2006.06.082
P407
P577
2006-09-08T00:00:00Z